NCT07030400View on ClinicalTrials.gov

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Small Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia (CLL)
Interventions
DRUG

Bruton's tyrosine kinase inhibitor

BTKi

DRUG

B-Cell Lymphoma 2 Protein Inhibitor

BCL2i

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

AstraZeneca

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER